Charles River Laboratories Intl. Inc vs Alphabet Inc Class A — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Alphabet Inc Class A trades at $351.66 (market cap $4.24T). The key difference: Alphabet Inc Class A is far larger — about 298× Charles River Laboratories Intl. Inc's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Alphabet Inc Class A for 85 Days on average.
| CRL | GOOGL | |
|---|---|---|
Market Cap | $14.23B | $4.24T |
Volume | 1,176,885 | 23,392,850 |
Sector | Health | Media |
52-Week High | $310.77 | $402.62 |
52-Week Low | $149.93 | $236.59 |
Typical Hold Time | 33 Days | 85 Days |
Enterprise Value | $17.06B | $4.13T |
Dividend Yield | — | 0.25% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Alphabet (GOOGL) trades at $348.29, down 0.63% on the day, amid strong fundamental performance with Q2 2026 EPS beating expectations by 217%. The stock shows bullish technical signals with moving averages supporting upward momentum, while maintaining robust profitability metrics including 54.77% net income margin and 49.55% ROE. Recent developments include YouTube subscription price increases and AI infrastructure partnerships driving growth prospects.
With 87% analyst buy ratings and a $431.83 consensus target representing 24% upside, GOOGL presents compelling value at current levels. Key risks include antitrust scrutiny and AI competition, but strong cash flow generation and consistent earnings beats support long-term growth trajectory. The company's diversified revenue streams and AI leadership position it well for sustained outperformance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →